Vitamin D3 for Cancer: The VITAL Trial, the 25% Mortality Reduction, and Why Your Target Level Matters

The Bottom Line

The largest vitamin D cancer prevention trial ever conducted, VITAL (25,871 participants, NEJM 2019), found no effect on cancer incidence but a 25% reduction in cancer mortality in updated analyses excluding the first two years. This nuanced result is important: vitamin D may not prevent cancer from developing, but it may help your body fight it once it appears. The effect was strongest in people with normal BMI and those who maintained blood levels above 40 ng/mL (100 nmol/L). At $5-10/month for supplements, the risk-benefit ratio is strongly favorable.

The VITAL Trial (What It Actually Showed)

The VITamin D and OmegA-3 TriaL enrolled 25,871 US adults (12,927 men ≥50 and 13,944 women ≥55) in a randomized, double-blind, placebo-controlled trial:

• Intervention: 2,000 IU vitamin D3 daily vs. placebo (in a 2x2 factorial design with omega-3 fatty acids)
• Follow-up: Median 5.3 years
• Cancer incidence: HR 0.96 (95% CI 0.88-1.06). Not significant. Vitamin D did not prevent new cancers.
• Cancer mortality: HR 0.83 (95% CI 0.67-1.02) in the primary analysis. When excluding the first 2 years (latency period): HR 0.75, statistically significant 25% reduction.

The 2-year exclusion is standard in cancer prevention analysis because cancers present in the first 2 years were already developing before randomization and couldn't be prevented by the intervention.

Why Incidence vs. Mortality Diverge

This is the most interesting finding. Vitamin D doesn't seem to stop cancers from forming, but it appears to make cancers less lethal once they develop. Possible mechanisms:

• Immune surveillance: Vitamin D enhances NK cell and T-cell function, potentially improving the immune response to early tumors
• Differentiation: Vitamin D promotes cancer cell differentiation (making them behave more like normal cells, less aggressively)
• Anti-metastatic: Reduces cancer cell migration and invasion in preclinical models
• Slower progression: Some evidence that vitamin D-sufficient patients have slower-growing tumors

The Target Level Matters More Than the Dose

The most common mistake in vitamin D supplementation is focusing on the dose rather than the blood level. Key findings:

• Most cancer protection appears above 40 ng/mL (100 nmol/L) of 25-hydroxyvitamin D
• The conventional "sufficient" threshold of 30 ng/mL may be too low for cancer prevention
• A 2014 meta-analysis found the strongest inverse association between vitamin D levels and cancer mortality at concentrations above 40-60 ng/mL
• Individual response to supplementation varies enormously: some people need 1,000 IU to maintain 40 ng/mL, others need 5,000 IU or more
• Test, don't guess: Get a 25-hydroxyvitamin D blood test and adjust your dose to maintain 40-60 ng/mL

Specific Cancer Types

• Colorectal cancer: Strongest evidence. Multiple meta-analyses show 20-30% risk reduction with adequate vitamin D. The SUNSHINE trial showed that high-dose vitamin D (8,000 IU/day) improved progression-free survival in metastatic CRC.
• Breast cancer: Inverse association in epidemiological studies. VITAL subgroup analysis showed reduced incidence in women with BMI < 25.
• Prostate cancer: Mixed data. Some studies suggest benefit for aggressive disease.
• Lung cancer: Weak or null association in most studies.
• Overall mortality: Multiple meta-analyses show 10-15% all-cause mortality reduction with vitamin D supplementation. Cancer mortality is the primary driver.

Practical Protocol

• Get tested: 25-hydroxyvitamin D blood test (available for $30-50 at most labs)
• Target level: 40-60 ng/mL (100-150 nmol/L)
• Starting dose: 2,000-5,000 IU vitamin D3 daily (not D2)
• Take with fat: Vitamin D is fat-soluble. Absorption improves significantly when taken with a meal containing fat.
• Add K2: Vitamin K2 (MK-7 form, 100-200mcg) directs calcium to bones and away from arteries. Not required but recommended with D3.
• Retest in 3 months: Adjust dose based on blood levels
• Cost: $5-10/month for D3+K2 supplements

Safety

Vitamin D3 at recommended doses (2,000-5,000 IU/day) is very safe:

• Toxicity is rare and requires sustained intake above 10,000 IU/day for months
• Hypercalcemia is the primary toxicity concern (monitor calcium if taking >5,000 IU/day long-term)
• Kidney stones: very slight increase in risk with supplementation. K2 may mitigate this.
• Drug interactions: minimal at standard doses

Our Assessment

Vitamin D3 isn't a cancer cure. The VITAL trial made that clear: it doesn't prevent cancers from forming. But the 25% reduction in cancer mortality is clinically meaningful and biologically plausible. Combined with the all-cause mortality benefit, the virtually zero risk at standard doses, and the $5/month cost, vitamin D3 supplementation to achieve blood levels of 40-60 ng/mL is one of the most evidence-supported, cost-effective interventions in the cancer prevention space. The only catch is that you need to actually test your blood level, not just take a pill and hope.

Sources

• NEJM 2019;380:33-44: VITAL trial principal results nejm.org
• PMC7089819: VITAL updated meta-analyses, cancer mortality signal pmc.ncbi.nlm.nih.gov
• NCI Vitamin D and Cancer fact sheet cancer.gov
• JAMA 2019: SUNSHINE trial (high-dose vitamin D in metastatic CRC)
• BMJ 2019: Vitamin D supplementation and total mortality meta-analysis

Related Research

• High-Dose Melatonin: The 34% Mortality Reduction (Grade B)
• Sulforaphane (Broccoli Sprouts) (Grade B)
• Exercise as Cancer Prevention (Grade A)
• The Anti-Cancer Protocol